937270-47-8|TG02/SB1317,is a pyrimidine-based derivative that inhibits CDKs together with JAK2 and FLT3. TG02 induces G1 cell cycle arrest and apoptosis in a broad range of tumor cell lines. TG02, originally designated SB1317, was discovered by S*BIO and licensed to TragaraPharmaceuticals in 2008. The in vitro kinase spectrum of TG02 is CDK9 (IC50: 3 nM), CDK5 (IC50: 4 nM), CDK2 (IC50: 5 nM), CDK3 (IC50: 8 nM) and CDK1 (IC50: 9 nM) . TG02 was selected for phase I clinical trials and the results are expected in 2014 for the phase 1 study in patients with chronic lymphocytic leukemia and small symphocytic symphoma and in 2015 for phase I study in patients with advanced hematological malignancies
Copyright © 2014-2015 Tubepharm. All Rights Reserved.
Tel：+86 021 5433 8626 Fax：+86 021 5433 8626*801 E-mail: firstname.lastname@example.org
All of our products, unless clearly indicated otherwise, are sold for research or manufacturing purposes only, are not for human, veterinary and household use.
The products under valid patent protection are not offered at this time. It is fully client's responsibility to comply with the rules, regulations and patent laws.